Investor Update
I'm most impressed with the BIS technology & benefits it offers to all participants in the health system.
I'm less impressed with the executive leadership team and the narrow vision they display in setting their goals.
I was wanting to get excited by the company and listened to some "Open Briefing" audio's with the CEO
& now the newly appointed Managing Director Richard Carry-on.
They were recorded in Sep and Nov 2014 after the historic Medical Reimbursement decision & rate setting.
He does not inspire confidence -
IMO he was lacking in focus on many fronts.
I see the benefits of the L-Dex system selling itself to patients and clinicians.
It should see fantastic market penetration rates in the next few years.
It does not need an empire of sales people which the MD seems to press.
A simplification of their business model by charging say a $30-50 royalty fee per set of readings might be a quicker and more lucrative avenue to success.
The balance of the Medicare refund of $121.67 could then be paid to the accredited nurse/clinician performing the test. This would help empower would-be providers & incentivize the L-Dex up-take.
Good luck to holders - This company has an outstanding technology platform but ?????
IPD Price at posting:
91.0¢ Sentiment: Hold Disclosure: Not Held
